Intensive experiments are not being performed in England because of several coronavirus species that were first discovered in India, although the government says so, the Guardian has learned.
corona virus different B.1.617 and “diversification research” in the UK, along with its close relatives B.1.617.2 and B.1.617.3. All of these worries scientists because they have one or two changes in their proteins that can help them to respond to immune responses and excretion.
If such grievances are met, they can be referred to as “various stakeholders”. The Guardian is aware that Public Health England does not test the test – while people with postcodes are asked to test it – until their species is named. This is true even of the health secretary, Matt Hancock, say on April 19th blood tests are done differently in India.
PHE told the Guardian that instead of doing this, it is using “experiments”. This is well known – for example trying to connect with people who are known to be of Indian descent, or people who may be living in the same areas as any of these.
Dr Susan Hopkins, director of Covid-19 at PHE, said: “We are continuing to investigate a number of linked cases in England. PHE health security teams are developing ways to identify health issues and reduce their impact on communities. Improve communication and testing and testing. an effective way to reduce the spread.
“This defensive approach ensures that our medical response remains complex and straightforward,” he added. “At present there is no evidence that the variant causes a dangerous disease or provides a vaccine that has been used so far but much work is being done to understand this.”
Paul Hunter, a professor of medicine at the University of East Anglia, said that with the growing number of Indian nationals, there was a need for urgent action.
“We are seeing the most recent, if the blood test has not yet started then B.1.617.2 is probably spreading so early that testing can play a sufficient role in reducing its spread,” he said.
According to Prof Ravi Gupta of the University of Cambridge, preliminary data From its data it is shown that the short-term mutation found in B.1.617 means that antibodies produced by the same Pfizer vaccine have a four to six times less potential to reduce variability compared to an earlier version of the virus, although changes were observed together. It is down to the fact that the ten cuts that occur with the E484K transition are noticeable at times, such as those first discovered in South Africa.
The group has added that B.1.617 may be more contagious than the virus.
According to information from the Covid-19 Genomics UK Consortium, 828 species in India have been found up to 28 April, including 260 of B.1.617 and 552 of B.1.617.2. This is in addition to the 744 different categories that were first available in South Africa, which were classified as “other needs”.
It is unknown at this time what he will do after leaving the post. But experts say their findings from Wellcome Sanger Institute’s Covid-19 genomic survementance paint a very disturbing picture.
This page includes genomes that are run for analysis but not from testing or experimental testing, and it shows that 10% of Covid’s successive cases in London are now related to B.1.617 or its close relatives.
Professor Christina Pagel, director of the clinical operating unit of University College London, said this was in line with a recent PHE report which showed that approximately 25% of Indian cases could be public cases. He also said that the rapid rise in litigation meant experimental comparisons were more appropriate than experimental experiments and compliance.
“They really need a blood test because it seems to be spreading rapidly in this area,” he said.